Vmbook Online ordering

Arch Therapeutics Inc

Arch Therapeutics, Inc. is a publicly traded medical device company based in the United States. The company is focused on the development and commercialization of innovative technologies for the surgical and trauma markets. Its flagship product is the AC5™ Topical Hemostatic Device, which is designed to control bleeding and help promote healing in various surgical and trauma applications.

Arch Therapeutics is listed on the Nasdaq stock exchange under the ticker symbol "ARTH". As of March 24, 2023, the company's stock price is $0.342 per share, giving it a market capitalization of around $14.6 million. The company's financials have been variable in recent years, with revenue of $58,000 in 2021 and a net loss of $13.1 million in the same year.

It's worth noting that investing in public companies always carries some level of risk, and it's important to do thorough research and consider seeking advice from a financial advisor before making any investment decisions. Additionally, the stock price and financial performance of Arch Therapeutics, like any publicly traded company, can be affected by a variety of factors, including market conditions, regulatory approvals, clinical trial results, and company financials, among others.